LakeShore Biopharma Announces Leadership Change With New Chairman Appointment

TipRanksMay 12 19:07

LakeShore Biopharma Enters Financing Lease Agreement for RMB110 Million

TipRanksMay 6 19:17

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA Rabies Vaccine (Vero Cell)

PR NewswireApr 23 21:35

Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket

BenzingaApr 10 17:26

There's No Escaping LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Muted Revenues Despite A 26% Share Price Rise

Simply Wall StJan 1 18:11

Lakeside Biological released its unaudited financial performance for the first half of the 2025 fiscal year and updated the financial guidance for the entire year.

In the first half of the 2025 fiscal year, revenue reached 0.3719 billion yuan, a year-on-year increase of 36.2%. The gross profit for the first half of the 2025 fiscal year was 0.3073 billion yuan, an increase of 39.1% year-on-year; the gross margin increased from 80.9% in the same period last year to 82.6%. Total operating expenses in the first half of the 2025 fiscal year decreased by 31.6%, totaling 0.2764 billion yuan. The net income for the first half of the 2025 fiscal year was 20.58 million yuan, while the net income under non-GAAP was 30.45 million yuan; in the same period of 2024, the recorded figures were (under GAAP and non-GAAP.

PR NewswireDec 20, 2024 11:05